AR055671A1 - Proceso de fabricacion de derivados de quinazolina - Google Patents

Proceso de fabricacion de derivados de quinazolina

Info

Publication number
AR055671A1
AR055671A1 ARP060104320A ARP060104320A AR055671A1 AR 055671 A1 AR055671 A1 AR 055671A1 AR P060104320 A ARP060104320 A AR P060104320A AR P060104320 A ARP060104320 A AR P060104320A AR 055671 A1 AR055671 A1 AR 055671A1
Authority
AR
Argentina
Prior art keywords
compound
formula
manufacture
salt
quinazoline derivatives
Prior art date
Application number
ARP060104320A
Other languages
English (en)
Inventor
J Blixt
M Goolden
P Hogan
D Martin
F Montgomery
J Pittman
G Sependa
Cristopher Jhon Squire
N Wright
Z Patel
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055671(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR055671A1 publication Critical patent/AR055671A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Procesos químicos para la fabricacion de determinados derivados de quinazolina, o sales de éstos aceptables para el uso farmacéutico. Procesos para a fabricacion de determinados intermediarios utiles en la fabricacion de los derivados de quinazolina, y procesos para la fabricacion de los derivados de quinazolina utilizando dichos intermediarios. en particular, la presente se relaciona con procesos químicos e intermediarios utiles en la fabricacion del compuesto 4-(4-bromo-2- fluoroanilino)-6-metoxi-7-(1-metilpiperidin-4-ilmetoxi)quinazolina. Reivindicacion 22: un proceso para la fabricacion de 7-(1-ter-butoxicarbonil)piperidin-4-ilmetoxi)-4-(4-bromo-2-fluoroanilino)-6-metoxiquinazolina, un compuesto de formula (10) a partir de 7-hidroxi-4-(4-bromo-2-fluoroanilino)-6-metoxiquinazolina, un compuesto de formula (9) caracterizado porque el proceso comprende los siguientes pasos: (l) hacer reaccionar el compuesto de formula (9) con un compuesto de formula (2) en presencia de una base apropiada., para proporcionar un compuesto de formula (10), o una sal de éste; y (m) aislar el compuesto de formula (10): (m-1) agregando agua y permitiendo que ocurra la cristalizacion del compuesto de formula (10), recolectando el compuesto de formula (10) y lavando el compuesto de formula (10) con agua, seguida por un solvente seleccionado entre acetato de etilo, acetato de butilo y acetonitrilo, a una temperatura en el rango de entre 25 y 55°C; o (m-2) agregando agua y un alcohol seleccionado entre metanol, etanol, isopropanol y n-propanol, y permitiendo que ocurra la cristalizacion del compuesto de formula (10), recolectando el compuesto de formula (10), y lavando el compuesto de formula (10) con una mezcla de agua y el alcohol seleccionado entre metanol, etanol, isopropanol y n-propanol, seguido por un solvente seleccionado entre acetato de etilo, acetato de butilo y acetonitrilo, a una temperatura en el rango de entre 25 y 55°C; y luego el compuesto de formula (10), obtenido en forma de base libre, puede convertirse en una forma de sal, y el compuesto de formula (10), obtenido en una forma de sal, puede convertirse en la base libre, o en forma de una sal alternativo, de ser necesario.
ARP060104320A 2005-09-30 2006-09-29 Proceso de fabricacion de derivados de quinazolina AR055671A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0519879.1A GB0519879D0 (en) 2005-09-30 2005-09-30 Chemical process

Publications (1)

Publication Number Publication Date
AR055671A1 true AR055671A1 (es) 2007-08-29

Family

ID=35395001

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104320A AR055671A1 (es) 2005-09-30 2006-09-29 Proceso de fabricacion de derivados de quinazolina

Country Status (32)

Country Link
US (8) US8163926B2 (es)
EP (2) EP1943240B1 (es)
JP (2) JP5213715B2 (es)
KR (1) KR101307641B1 (es)
CN (3) CN102503898B (es)
AR (1) AR055671A1 (es)
AT (2) ATE448218T1 (es)
AU (1) AU2006296367B2 (es)
BR (1) BRPI0616715A2 (es)
CA (2) CA2624045C (es)
CY (2) CY1110275T1 (es)
DE (2) DE602006010428D1 (es)
DK (2) DK1943240T3 (es)
ES (2) ES2335435T3 (es)
GB (1) GB0519879D0 (es)
HK (2) HK1122553A1 (es)
HR (2) HRP20100019T1 (es)
IL (2) IL190172A (es)
ME (2) ME01466B (es)
MY (2) MY149834A (es)
NO (1) NO342152B1 (es)
NZ (2) NZ593930A (es)
PL (2) PL2053048T3 (es)
PT (2) PT2053048E (es)
RS (2) RS51515B (es)
RU (1) RU2448102C2 (es)
SG (1) SG165416A1 (es)
SI (2) SI2053048T1 (es)
TW (2) TWI328580B (es)
UY (1) UY29824A1 (es)
WO (1) WO2007036713A2 (es)
ZA (1) ZA200802416B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101607958A (zh) * 2002-02-01 2009-12-23 阿斯特拉曾尼卡有限公司 喹唑啉化合物
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
US7851623B2 (en) * 2006-11-02 2010-12-14 Astrazeneca Ab Chemical process
EP2404595B1 (de) * 2011-09-01 2015-08-05 Symrise AG Verfahren zur Herstellung von Indanon-Derivaten
AU2013304102B2 (en) * 2012-08-15 2016-09-01 Glaxo Group Limited Chemical process
CN104098544A (zh) * 2013-04-07 2014-10-15 浙江九洲药物科技有限公司 一种凡德他尼的制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870083A (en) * 1987-11-24 1989-09-26 Merrell Dow Pharmaceuticals Inc. 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants
JP2829744B2 (ja) 1989-05-31 1998-12-02 川研ファインケミカル株式会社 ピペリジンカルボン酸類の製造方法
WO1992006086A1 (en) 1990-10-01 1992-04-16 Janssen Pharmaceutica N.V. Novel 4-piperidinylcarbonyl derivatives
ATE231505T1 (de) 1991-03-28 2003-02-15 Eisai Co Ltd Neue heterocyclische/cyclische amine
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2118117A1 (en) 1993-02-18 1994-08-19 Shigeki Fujiwara Adenosine uptake inhibitor
ATE171446T1 (de) * 1993-05-26 1998-10-15 Syntex Inc 1-phenylalkanone als 5-ht4 rezeptor ligande
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE69504300T2 (de) * 1994-01-13 1999-04-29 Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire Gem-bissubstituierte azazyclische tachykinin-antagonisten
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
PT1244647E (pt) * 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
ATE468339T1 (de) 2001-12-20 2010-06-15 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
CN101607958A (zh) 2002-02-01 2009-12-23 阿斯特拉曾尼卡有限公司 喹唑啉化合物
AU2003207291A1 (en) 2002-02-06 2003-09-02 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
CA2495487A1 (en) 2002-08-09 2004-02-19 Astrazeneca Ab Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
WO2004071397A2 (en) 2003-02-13 2004-08-26 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
CA2531862C (en) 2003-07-10 2011-10-25 Astrazenca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process

Also Published As

Publication number Publication date
HK1130478A1 (en) 2009-12-31
SI2053048T1 (sl) 2010-12-31
US20120095229A1 (en) 2012-04-19
JP5654546B2 (ja) 2015-01-14
ES2350513T3 (es) 2011-01-24
NO342152B1 (no) 2018-04-03
JP5213715B2 (ja) 2013-06-19
IL227574A (en) 2015-08-31
RS51515B (en) 2011-06-30
GB0519879D0 (en) 2005-11-09
UY29824A1 (es) 2007-04-30
ME01466B (me) 2014-04-20
EP2053048B1 (en) 2010-09-15
US9815816B2 (en) 2017-11-14
US20240150317A1 (en) 2024-05-09
DK2053048T3 (da) 2010-11-29
CN101277948A (zh) 2008-10-01
IL190172A0 (en) 2008-08-07
SI1943240T1 (sl) 2010-02-26
EP1943240B1 (en) 2009-11-11
US20180118716A1 (en) 2018-05-03
IL190172A (en) 2014-05-28
US8865899B2 (en) 2014-10-21
KR101307641B1 (ko) 2013-09-12
EP2053048B8 (en) 2011-09-21
RU2448102C2 (ru) 2012-04-20
ZA200802416B (en) 2009-01-28
HK1122553A1 (en) 2009-05-22
CA2745829C (en) 2013-07-02
CA2745829A1 (en) 2007-04-05
CA2624045A1 (en) 2007-04-05
ME01531B (me) 2014-04-20
CA2624045C (en) 2012-05-22
PL1943240T3 (pl) 2010-04-30
BRPI0616715A2 (pt) 2011-06-28
RS51263B (sr) 2010-12-31
AU2006296367B2 (en) 2011-08-11
CN102503898B (zh) 2015-03-25
HRP20100620T1 (hr) 2010-12-31
DE602006017004D1 (de) 2010-10-28
DK1943240T3 (da) 2010-03-01
NZ593930A (en) 2013-02-22
ATE481399T1 (de) 2010-10-15
TWI424991B (zh) 2014-02-01
US20090203905A1 (en) 2009-08-13
WO2007036713A3 (en) 2007-06-14
US20160185754A1 (en) 2016-06-30
CN101277948B (zh) 2013-03-13
KR20080049114A (ko) 2008-06-03
SG165416A1 (en) 2010-10-28
ES2335435T3 (es) 2010-03-26
CN102503933A (zh) 2012-06-20
WO2007036713A2 (en) 2007-04-05
CN102503898A (zh) 2012-06-20
EP1943240A2 (en) 2008-07-16
US8163926B2 (en) 2012-04-24
DE602006010428D1 (de) 2009-12-24
EP2053048A1 (en) 2009-04-29
US20190263782A1 (en) 2019-08-29
NZ566566A (en) 2011-08-26
JP2013063998A (ja) 2013-04-11
CY1110275T1 (el) 2015-01-14
CY1110887T1 (el) 2015-06-10
NO20081267L (no) 2008-04-30
US20140378684A1 (en) 2014-12-25
PT2053048E (pt) 2010-11-10
TWI328580B (en) 2010-08-11
PL2053048T3 (pl) 2011-03-31
US20220033377A1 (en) 2022-02-03
MY145540A (en) 2012-02-29
US10344015B2 (en) 2019-07-09
TW200745036A (en) 2007-12-16
HRP20100019T1 (hr) 2010-02-28
JP2009510039A (ja) 2009-03-12
AU2006296367A1 (en) 2007-04-05
TW201018660A (en) 2010-05-16
PT1943240E (pt) 2010-01-11
ATE448218T1 (de) 2009-11-15
CN102503933B (zh) 2014-06-25
MY149834A (en) 2013-10-31
RU2008116573A (ru) 2009-11-10

Similar Documents

Publication Publication Date Title
AR055671A1 (es) Proceso de fabricacion de derivados de quinazolina
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
AR072962A1 (es) Derivados de pirimidin-4-ona sustituidos
ES2660146T3 (es) Sales del inhibidor de cdk
PE20110100A1 (es) Procedimiento de preparacion de n-[trans-4-[4-(ciclopropilmetil)-1-piperazinil]ciclohexil]-4-[[(7r)-7-etil-5,6,7,8-tetrahidro-5-metil-8-(1-metiletil)-6-oxo-2-pteridinil]amino]-3-metoxi-benzamida
AR043111A1 (es) Derivados monoacilados de o-fenilendiaminas
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b
AR062134A1 (es) Erlotinib cristalino
ATE507212T1 (de) Morpholine als 5ht2c-agonisten
AR063449A1 (es) Proceso quimico para derivados de quinazolina, intermediarios
AR049401A1 (es) Aza-biciclononanos
AR064692A1 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
PE20090770A1 (es) Derivados de benzoxazolona
RU2009117654A (ru) Получение азоксистробина
US11827605B2 (en) Isoquinoline compounds and their use in treating AhR imbalance
AR057525A1 (es) Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion
AR077301A1 (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b
JP2013531058A5 (es)
AR041678A1 (es) Formas cristalinas de clorhidrato de donepezil
MXPA05003695A (es) Nuevo proceso para la sintesis de compuestos de 1,3-dihidro-2h-3-benzazepin-2-ona, y aplicacion en la sintesis de ivabradina y sales de adicion de la misma con un acido farmaceuticamente aceptable.
UY29801A1 (es) Derivados de quinazolina, sales farmacéuticamente aceptables de las mismas, composiciones farmacéuticas conteniéndolas, procedimientos de preparación y aplicaciones.
AR055837A1 (es) Procedimientos para la preparacion de alc0holes aminoetoxibencilicos
BRPI0808570B8 (pt) processo para a preparação de inibidores de glyt-1
PE20070326A1 (es) Procedimiento para la preparacion de compuestos de 1-[ciano(4-hidroxifenil)metil]ciclohexanol
AR057147A1 (es) Procedimientos para preparar compuestos intermedios de heteroaril -amina

Legal Events

Date Code Title Description
FC Refusal